Pages that link to "Q43032909"

The following pages link to Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus (Q43032909):

Displaying 36 items.

• Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies (Q24568148) (← links)
• Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis (Q28275281) (← links)
• Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials (Q28294225) (← links)
• Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. (Q30240823) (← links)
• Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents (Q33731748) (← links)
• Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison (Q33785197) (← links)
• Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide. (Q34407865) (← links)
• Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials (Q35236019) (← links)
• Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis (Q36124544) (← links)
• Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in korean subjects with type 2 diabetes (Q36628919) (← links)
• Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes (Q37101632) (← links)
• Vildagliptin: a review of its use in type 2 diabetes mellitus (Q37801906) (← links)
• Vildagliptin in the treatment of type 2 diabetes mellitus (Q37890411) (← links)
• Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. (Q37910902) (← links)
• Managing diabetes in Asia: Overcoming obstacles and the role of DPP-IV inhibitors (Q37948434) (← links)
• The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials (Q37970749) (← links)
• Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis (Q38076330) (← links)
• The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis (Q38137027) (← links)
• Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes (Q38189114) (← links)
• The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. (Q38205588) (← links)
• Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. (Q38682317) (← links)
• Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients (Q38716033) (← links)
• Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions (Q38795046) (← links)
• Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies (Q39108666) (← links)
• Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients (Q40651201) (← links)
• Nanoparticle formulation by Büchi B-90 Nano Spray Dryer for oral mucoadhesion (Q41451480) (← links)
• Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management (Q41826517) (← links)
• Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan (Q42876103) (← links)
• Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension (Q44067944) (← links)
• Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus (Q47173429) (← links)
• Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, pl (Q51233383) (← links)
• Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus (Q51360460) (← links)
• Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. (Q53354332) (← links)
• Vildagliptin: a review of its use in type 2 diabetes mellitus (Q87461871) (← links)
• Mucoadhesive Particles: A Novel, Prolonged-Release Nanocarrier of Sitagliptin for the Treatment of Diabetics (Q91793450) (← links)
• Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials (Q98188564) (← links)